A way to close off diseased blood vessels with unprecedented accuracy using a zap of laser light has been tested in mice.
The technique developed by Canadian, British and American researchers could be used to shut off blood vessels to treat certain tumours or a common eye disease.
It is a significant upgrade to an existing treatment called photodynamic therapy (PDT), which involves injecting a light-sensitive compound into diseased tissue. Exposing the compound to laser light generates a high-energy form of oxygen that is toxic to cells.
Advertisement
Using standard PDT, it is very difficult to focus the effect onto diseased cells without destroying adjacent healthy tissue. And the laser light needed can only penetrate 1 centimetre into the tissue.
A new compound made by and colleagues at Oxford University can tackle both those problems.
Extreme accuracy
Each molecule of the new drug is able to absorb two photons instead of just one, as for current PDT compounds. The drug displays a physical phenomenon known as , which means much less energy is needed to perform the procedure.
As a result, low-energy near-infrared light can be used, which can penetrate two or three times deeper into living tissue, depending on the particular tissue. That would allow many more uses for PDT.
The process is also more accurate, explains Anderson. The underlying physics means the amount of two-photon excitation declines extremely rapidly with increasing distance from the focus of the laser beam.
In tests on living mice, of the University of Toronto, Canada, and colleagues, were able to close blood vessels with 鈥渆xquisite spatial selectivity鈥�, using pulses of laser light to 鈥渄raw鈥� along vessels they wanted to close.
鈥楳any possibilities鈥�
鈥淭he most immediate application is treating [advanced] age-related macular degeneration (AMD) by closing off unwanted blood capillaries,鈥� Anderson told 快猫短视频. 鈥淚t might also be used to treat certain tumours, particularly where improved accuracy is required.鈥�
The team will now go on to investigate the toxicology of the new photosensitive drug, and test its efficacy against tumours. 鈥淲e are also experimenting with related compounds in an attempt to improve uptake by cells,鈥� adds Anderson.
鈥淭his paper is a breakthrough in two-photon PDT and I would mark it as in the top five important results for biophotonics in the past year,鈥� commented David Cramb of the University of Calgary, Alberta, Canada, who also works on PDT.
Attempts to make drugs capable two-photon excitation have faltered in the past, says Cramb. 鈥淭here are many possibilities for this [new] technique 鈥� with the most obvious being for treating AMD.鈥�
Journal reference:
